Nalpropion Pharmaceuticals LLC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersBrentwood, TN
US patents14
SAM.gov UEIFVNSDJP8YDN1
CAGE code89HB0
Incorporated inDE
- medicines
- chronic progressive diseases
- therapies
- CONTRAVE®
- ONZETRA®
- SILENOR®
- TREXIMET®
- patients living
- healthcare
Named on the company’s own website, read JUL 29, 2026
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
14 US patents granted 2019–2024, 8 of them in the five years to SEP 2025.
Pharmaceuticals 14
- Methods for administering weight loss medicationsUS 12,048,769 · granted JUL 30, 2024
- Compositions and methods for reducing major adverse cardiovascular eventsUS 11,998,542 · granted JUN 4, 2024
- Methods for treating visceral fat conditionsUS 11,324,741 · granted MAY 10, 2022
- Compositions for affecting weight lossUS 11,278,544 · granted MAR 22, 2022
- Methods of treating overweight and obesityUS 11,139,056 · granted OCT 5, 2021
Newest 5 shown · Granted to Nalpropion Pharmaceuticals LLC · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | Brentwood | TN | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


